Systemic Biologic Management of Atopic Dermatitis

Diem-Phuong D Dao; R Hal Flowers

doi:10.1007/978-3-031-54513-9_13

Systemic Biologic Management of Atopic Dermatitis

Adv Exp Med Biol. 2024:1447:139-149. doi: 10.1007/978-3-031-54513-9_13.

Authors

Diem-Phuong D Dao¹, R Hal Flowers²

Affiliations

¹ Virginia Commonwealth University, School of Medicine, School of Medicine, Richmond, VA, USA. daopd@vcu.edu.
² University of Virginia, Department of Dermatology, Charlottesville, VA, USA.

PMID: 38724791
DOI: 10.1007/978-3-031-54513-9_13

Abstract

Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are effective in clinical trials at improving atopic dermatitis. With a good safety profile and low-risk adverse events, dupilumab and tralokinumab are generally excellent treatment options for patients with severe or refractory atopic dermatitis.

Keywords: Adverse effects; Atopic dermatitis; Biologics; Clinic trial; Dupilumab; IL-4 receptor inhibition; Immunomodulators; Pharmacokinetics; Tralokinumab; Biologic agents.

Publication types

Review

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / therapeutic use
Biological Therapy / methods
Dermatitis, Atopic* / drug therapy
Dermatitis, Atopic* / immunology
Humans
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal
tralokinumab